GSK plc
GSK40.830USD
-0.650-1.57%
Close 09/12, 16:00（ET）Quotes delayed by 15 min
84.62BMarket Cap
19.13P/E TTM
More Details of GSK plc Company
GSK plc is a global biopharma company. The Company’s segments include Commercial Operations and Research and Development. It develops cancer medicines for patients, including ovarian cancer, endometrial cancer, and multiple myeloma. Its product areas include vaccines, specialty medicines, and general medicine. It is also focused on addressing the unmet treatment needs of patients with respiratory and inflammatory conditions. Its vaccine portfolio includes over 20 vaccines that help to protect people from a range of diseases and infections, including meningitis, shingles and flu, among others. Its specialty medicines are also engaged in developing medicines for respiratory disease and HIV. Its general medicines include inhaled medicines for asthma and chronic obstructive pulmonary disease, antibiotics, and medicines for skin diseases. It is advancing oligonucleotide therapeutics in chronic hepatitis B and steatotic liver disease as well as other therapeutic areas beyond liver disease.
Company Info
Ticker SymbolGSK
Company nameGSK plc
IPO dateMay 22, 1972
CEOMs. Deborah Waterhouse
Number of employees68629
Security typeOrdinary Share
Fiscal year-endMay 22
Address980 Great West Road
CityBRENTFORD
Stock exchangeLondon Stock Exchange
CountryUnited Kingdom
Postal codeTW8 9GS
Phone442080475000
Websitehttps://www.gsk.com/
Ticker SymbolGSK
IPO dateMay 22, 1972
CEOMs. Deborah Waterhouse
Company Executives
Name
Name/Position
Position
Shareholding
Change
Dr. Hal V. Barron, M.D.
Dr. Hal V. Barron, M.D.
Non-Executive Director
Non-Executive Director
654.96K
+0.52%
Ms. Shobie Ramakrishnan
Ms. Shobie Ramakrishnan
Chief Digital and Technology Officer
Chief Digital and Technology Officer
484.20K
+0.09%
Mr. Charles A. (Charlie) Bancroft
Mr. Charles A. (Charlie) Bancroft
Senior Independent Non-Executive Director
Senior Independent Non-Executive Director
36.69K
+1.00%
Ms. Elizabeth McKee (Liz) Anderson
Ms. Elizabeth McKee (Liz) Anderson
Independent Non-Executive Director
Independent Non-Executive Director
2.74K
+1.00%
Dr. Jeannie Lee
Dr. Jeannie Lee
Independent Non-Executive Director and Scientific & Medical Expert
Independent Non-Executive Director and Scientific & Medical Expert
1.32K
+0.84%
Dr. Harry C. (Hal) Dietz
Dr. Harry C. (Hal) Dietz
Independent Non-Executive Director, Scientific and Medical Expert
Independent Non-Executive Director, Scientific and Medical Expert
--
--
Mr. James Ford
Mr. James Ford
Senior Vice President, Group General Counsel, Legal and Compliance
Senior Vice President, Group General Counsel, Legal and Compliance
--
--
Ms. Sally Jackson
Ms. Sally Jackson
Senior Vice President - Global Communications and CEO Office
Senior Vice President - Global Communications and CEO Office
--
--
Dr. Tony Wood, Ph.D.
Dr. Tony Wood, Ph.D.
Chief Scientific Officer
Chief Scientific Officer
--
--
Ms. Julie Brown
Ms. Julie Brown
Chief Financial Officer, Executive Director
Chief Financial Officer, Executive Director
--
--
View more
Name
Name/Position
Position
Shareholding
Change
Dr. Hal V. Barron, M.D.
Dr. Hal V. Barron, M.D.
Non-Executive Director
Non-Executive Director
654.96K
+0.52%
Ms. Shobie Ramakrishnan
Ms. Shobie Ramakrishnan
Chief Digital and Technology Officer
Chief Digital and Technology Officer
484.20K
+0.09%
Mr. Charles A. (Charlie) Bancroft
Mr. Charles A. (Charlie) Bancroft
Senior Independent Non-Executive Director
Senior Independent Non-Executive Director
36.69K
+1.00%
Ms. Elizabeth McKee (Liz) Anderson
Ms. Elizabeth McKee (Liz) Anderson
Independent Non-Executive Director
Independent Non-Executive Director
2.74K
+1.00%
Dr. Jeannie Lee
Dr. Jeannie Lee
Independent Non-Executive Director and Scientific & Medical Expert
Independent Non-Executive Director and Scientific & Medical Expert
1.32K
+0.84%
Dr. Harry C. (Hal) Dietz
Dr. Harry C. (Hal) Dietz
Independent Non-Executive Director, Scientific and Medical Expert
Independent Non-Executive Director, Scientific and Medical Expert
--
--
Revenue Breakdown
Currency: USDUpdated: Sun, Jul 6
Currency: USDUpdated: Sun, Jul 6
FY2025Q1
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2021
FY2020
FY2019
No Data
By RegionUSD
Name
Revenue
Proportion
US
4.72B
49.92%
Rest of world
2.54B
26.81%
Europe
2.20B
23.27%
By Business
By Region
No Data
Shareholding Stats
Updated: Sun, Aug 17
Updated: Sun, Aug 17
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
Dodge & Cox
3.87%
Fidelity Management & Research Company LLC
2.53%
Fisher Investments
1.54%
PRIMECAP Management Company
1.36%
JTC Employer Solutions Trusteee Ltd
0.74%
Other
89.96%
Shareholders
Shareholders
Proportion
Dodge & Cox
3.87%
Fidelity Management & Research Company LLC
2.53%
Fisher Investments
1.54%
PRIMECAP Management Company
1.36%
JTC Employer Solutions Trusteee Ltd
0.74%
Other
89.96%
Shareholder Types
Shareholders
Proportion
Investment Advisor
9.61%
Investment Advisor/Hedge Fund
7.36%
Research Firm
1.05%
Hedge Fund
0.82%
Bank and Trust
0.11%
Individual Investor
0.06%
Pension Fund
0.05%
Insurance Company
0.05%
Family Office
0.03%
Other
80.86%
Institutional Shareholding
Updated: Tue, Jul 1
Updated: Tue, Jul 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q2
1478
378.08M
18.54%
+5.70M
2025Q1
1494
378.46M
18.50%
+5.08M
2024Q4
1481
355.06M
17.14%
+27.38M
2024Q3
1472
319.97M
15.44%
-30.07M
2024Q2
1585
322.06M
15.54%
-29.11M
2024Q1
1617
318.91M
15.39%
-23.52M
2023Q4
1614
299.81M
14.57%
-35.71M
2023Q3
1570
293.92M
14.35%
-37.46M
2023Q2
1545
286.58M
13.99%
-41.88M
2023Q1
1546
281.08M
13.72%
-55.01M
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
Dodge & Cox
78.65M
3.85%
+10.21M
+14.92%
Mar 31, 2025
Fidelity Management & Research Company LLC
50.60M
2.48%
+6.83M
+15.61%
Mar 31, 2025
Fisher Investments
30.03M
1.47%
+11.20M
+59.43%
Mar 31, 2025
PRIMECAP Management Company
25.71M
1.26%
+446.36K
+1.77%
Mar 31, 2025
JTC Employer Solutions Trusteee Ltd
15.26M
0.75%
-5.02M
-24.75%
Mar 31, 2025
Fidelity Institutional Asset Management
9.52M
0.47%
+465.88K
+5.15%
Mar 31, 2025
T. Rowe Price International Ltd
7.72M
0.38%
+155.40K
+2.05%
Mar 31, 2025
RBC Capital Markets Wealth Management
6.25M
0.31%
+438.49K
+7.54%
Mar 31, 2025
State Street Global Advisors (US)
6.97M
0.34%
-52.09K
-0.74%
Mar 31, 2025
Goldman Sachs Asset Management, L.P.
8.47M
0.41%
-380.46K
-4.30%
Mar 31, 2025
View more
Related ETFs
Updated: Sat, Sep 6
Updated: Sat, Sep 6
Name
Proportion
VanEck Pharmaceutical ETF
6.11%
USCF Dividend Income Fund
3.98%
The Opal International Dividend Income ETF
3.96%
Keating Active ETF
3.28%
Sound Equity Dividend Income ETF
3.26%
Brandes International ETF
2.84%
GMO International Value ETF
2.18%
Altrius Global Dividend ETF
1.83%
Fidelity Blue Chip Value ETF
1.35%
Fidelity Women's Leadership ETF
1.01%
View more
VanEck Pharmaceutical ETF
Proportion6.11%
USCF Dividend Income Fund
Proportion3.98%
The Opal International Dividend Income ETF
Proportion3.96%
Keating Active ETF
Proportion3.28%
Sound Equity Dividend Income ETF
Proportion3.26%
Brandes International ETF
Proportion2.84%
GMO International Value ETF
Proportion2.18%
Altrius Global Dividend ETF
Proportion1.83%
Fidelity Blue Chip Value ETF
Proportion1.35%
Fidelity Women's Leadership ETF
Proportion1.01%
Dividend
A total of
20.79B
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
Feb 05, 2025
GSK.NB Approximate interim Cash Dividend of gross USD 0.400652 paid on Apr 10, 2025 going ex on Feb 21, 2025
Feb 21, 2025
Apr 10, 2025
Feb 21, 2025
Oct 30, 2024
GSK.NB Final Cash Dividend of gross USD 0.376892 paid on Jan 09, 2025 going ex on Nov 15, 2024
Nov 15, 2024
Jan 09, 2025
Nov 15, 2024
Jul 31, 2024
GSK.NB Interim Cash Dividend of gross USD 0.392813 paid on Oct 10, 2024 going ex on Aug 16, 2024
Aug 16, 2024
Oct 10, 2024
Aug 16, 2024
May 01, 2024
GSK.NB Interim Cash Dividend of gross USD 0.384301 paid on Jul 11, 2024 going ex on May 16, 2024
May 17, 2024
Jul 11, 2024
May 16, 2024
Feb 01, 2024
GSK.NB Interim Cash Dividend of gross USD 0.404885 paid on Apr 11, 2024 going ex on Feb 22, 2024
Feb 23, 2024
Apr 11, 2024
Feb 22, 2024
Nov 01, 2023
GSK.NB Final Cash Dividend of gross USD 0.356356 paid on Jan 11, 2024 going ex on Nov 16, 2023
Nov 17, 2023
Jan 11, 2024
Nov 16, 2023
Jul 26, 2023
GSK.NB Interim Cash Dividend of gross USD 0.343532 paid on Oct 12, 2023 going ex on Aug 17, 2023
Aug 18, 2023
Oct 12, 2023
Aug 17, 2023
Apr 26, 2023
GSK.NB Interim Cash Dividend of gross USD 0.360944 paid on Jul 13, 2023 going ex on May 18, 2023
May 19, 2023
Jul 13, 2023
May 18, 2023
Feb 01, 2023
GSK.NB Interim Cash Dividend of gross USD 0.341883 paid on Apr 13, 2023 going ex on Feb 23, 2023
Feb 24, 2023
Apr 13, 2023
Feb 23, 2023
Nov 02, 2022
GSK.NB Final Cash Dividend of gross USD 0.334785 paid on Jan 12, 2023 going ex on Nov 17, 2022
Nov 18, 2022
Jan 12, 2023
Nov 17, 2022
View more
Stock Split
Date
Type
Ratio
Jun 24, 2022
Merger
5→4
Jun 24, 2022
Merger
5→4
Jun 24, 2022
Merger
5→4
Jun 24, 2022
Merger
5→4
Date
Type
Ratio
Jun 24, 2022
Merger
5→4
Jun 24, 2022
Merger
5→4
Jun 24, 2022
Merger
5→4
Jun 24, 2022
Merger
5→4
